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Abstract
Background: Renal atrophy is observed in an irradiated kidney. The aim of this study was to determine dose-volume
histogram parameters and other factors that predict renal atrophy after 10-fraction stereotactic body radiotherapy
(SBRT) for primary renal cell carcinoma (RCC).
Methods: A total of 14 patients (11 males, 3 females) who received SBRT for RCC at Tohoku University Hospital between
April 2010 and February 2014 were analyzed. The median serum creatinine level was 1.1 mg/dl and two patients had a
single kidney. Nine patients were implanted with fiducial markers. The median tumor diameter was 30 mm. SBRT was
delivered at 70 Gy in 10 fractions for 7 tumors, at 60 Gy in 10 fractions for 2 tumors, and at 50 Gy in 10 fractions for 5
tumors with 6 and/or 15 MV X-ray using 5 to 8 multi-static beams. Renal atrophy was assessed using post-SBRT
CT images after 12–24 months intervals. Correlations were examined by Spearman rank correlation analysis.
Differences between two groups were evaluated by the Mann-Whitney test, and pairwise comparisons were
made by the Wilcoxon signed-rank test.
Results: The median tumor volume shrunk from 14.8 cc to 10.6 cc (p = 0.12), and the median irradiated kidney
volume changed from 160.4 cc to 137.1 cc (p < .01). The median peak creatinine level was 1.6 mg/dl after treatment
(p < .01). Percentage volumes of the irradiated kidney receiving at least 10 Gy (V10, p = 0.03), V20 (p < .01), V30
(p < .01), V40 (p = 0.01), mean irradiated kidney dose (p < .01), and magnitude of overlap between PTV and kidney
volume (p = 0.03) were significantly correlated with post-treatment irradiated kidney volume in percent, and
V20-V30 had strong correlation (r < −0.70, p < .01). Patients with implanted fiducial markers showed a significantly
lower ratio of renal atrophy (p = 0.02).
Conclusions: Significant renal atrophic change was observed. Dose distribution of SBRT at 20–30 Gy had a strong
correlation with renal atrophy when irradiation was performed in 10 fractions.
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Background
Much progress has been made in extracranial stereotac-
tic radiotherapy since the creation of a stereotactic body
frame and application of the frame to treatment [1]. In
thoracic malignancies, stereotactic body radiotherapy
(SBRT) has become one of the most powerful local ther-
apies and one of the most important treatment options
for early stage non-small cell lung cancer, especially in
elderly or inoperable patients [2]. Furthermore, pooled
analysis of the results of a recent prospective trial have
showed that survival rate and regional recurrence rate
after SBRT for stage I non-small cell lung cancer were
comparable to those after lobectomy [3]. Due to the pro-
gress in image-guided radiotherapy, SBRT has been ap-
plied to many other sites [4–6]. SBRT has sometimes
been used as a definitive treatment for localized prostate
cancer [4]. There has been an increasing number of re-
ports on SBRT for hepatocellular carcinoma with a high
rate of local control and acceptable toxicities [5].
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For renal cell carcinoma (RCC), surgical resection (i.e.,
nephrectomy) has been the standard treatment. One of
the reasons is that RCC is considered to be a radioresis-
tant tumor, but the kidney itself is considered to be
relatively radiosensitive [7]. Thus, radiotherapy for RCC
has been performed as palliative radiotherapy in most
cases or as postoperative radiotherapy in a limited set-
ting [8, 9]. However, in this SBRT era, several outcomes
of SBRT for primary RCC have been reported. Although
most of the clinical outcomes were reported from single
institutions, local control rates were 84–100 % and toxic-
ities rates were relatively low [10–13]. In Japan, a clinical
trial has been performed, and our institute took part in
the trial starting in April 2010 [14]. This is the multi-
center single arm clinical trial of SBRT for RCC, 50 Gy to
70 Gy in 10 fractions were prescribed within dose con-
straints of the organ at risk and primary endopoints were
toxicity and 3-year local progression-free rate.
Because the kidney is a radiosensitive organ, renal atro-
phy developed after abdominal radiotherapy despite expo-
sures to relatively low doses. A dose-volume histogram
(DVH) of renal atrophy 12 months after conventional
radiotherapy has been reported [15]. They reported that
percentage volumes of the primary irradiated kidney re-
ceiving at least 10 Gy, 15 Gy and 20 Gy were significantly
associated with renal atrophy. This renal remodeling is
also seen 12 months or more after SBRT, but, to the
best of our knowledge, there has been only a single case
report about post-SBRT renal atrophy [16]. Svedman
et al. reported SBRT for 7 renal lesions in patients with
one functional kidney [17]. Their results showed that
SBRT was safe, and none of their patients required dialysis.
Thus, SBRT for RCC is sometimes required for preserving
the postoperative remaining kidney. Although SBRT fo-
cuses a high dose to a local region with a high level of ac-
curacy, more studies are needed to achieve a higher level
of safety. In the present study, DVHs of kidneys treated
with a 10-session scheme of SBRT at our institute were
retrospectively analyzed. DVH predictive factors for renal
atrophy after SBRT intervals of 12–24 months and other
factors affecting renal atrophy were investigated.
Methods
Patients
Before treatment, all patients with RCC whose max-
imum tumor diameter was 50 mm or less were assessed
by a urologist. For patients who were judged to be inop-
erable, patients who were judged to be operable but for
whom SBRT was preferred and patients who refused
surgery, a radiation oncologist assessed the indication
for SBRT. SBRT for RCC was performed for 17 consecu-
tive patients at our institute between April 2010 and
February 2014. Of those patients, eligibility criteria for
current study were availability of follow-up CT images
taken 12–24 months after SBRT, no requirement for
hemodialysis before SBRT and no additional invasive
therapy (such as nephrectomy or radiofrequency abla-
tion) having been performed. Two patients underwent
hemodialysis before SBRT and one operable patient de-
clined to continue SBRT and underwent nephrectomy. A
total of 14 patients with 14 tumors were retrospectively
analyzed. The pretreatment characteristics of the pa-
tients are summarized in Table 1. Two patients had pre-
viously undergone nephrectomy and therefore had only
one kidney. Nine patients were implanted with one to
two gold fiducial markers in the kidney parenchyma near
the tumor before SBRT. None of the patients had a histo-
logically proven tumor, and assessment by radiologists
and a urologist was therefore needed. First, the dynamic
CT and MRI were interpreted by two or more radiologists,
and agreement with radiographic diagnosis of RCC was
needed. Second, the patients underwent examination by a
urologist. Operability was judged by the urologist. Assess-
ment that the patient was inoperable, the patient was
operable but SBRT was better option than surgical resec-
tion, or the patient was operable but refused surgery was
needed. Finally, patients received an explanation from a
radiation oncologist, and written informed consent was
obtained by the radiation oncologist. This study was ap-
proved by the Ethical Committee of Tohoku University
Table 1 Baseline characteristics of patients
Characteristics No. (%)











Administration of antithrombotic agents
Yes 10 (71)
No 4 (29)






Tumor diameter, median, mm 30 mm (range: 16–46 mm)
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Hospital (2011-100), and informed consent was obtained
from all patients.
Treatment protocol and SBRT procedure
Each patient was immobilized in the supine position
with a body frame (Vac-loc, Med-tek, Orange City, IA),
and movement of the implanted fiducial marker or dia-
phragm was measured to estimate respiratory tumor
motion using continuous X-ray images in a simulator
(Ximatron or Acuity system, Varian Medical Systems,
Palo Alto, CA). To control respiratory movement, ab-
dominal compression was used in 6 patients and the
breath hold technique was used in 1 patient. All patients
underwent a planning CT scan at a slice thickness of
2 mm with a multi-detector CT scanner (GE Light Speed
Qxi, GE Healthcare, Waukesha, WI); 7 patients underwent
a fast CT scan, 5 patients underwent a 4-dimensional CT
scan and 2 patients underwent a slow-rotation CT scan
(4 s/slice). The internal margin was determined from a
planning CT image and from movement of the implanted
fiducial marker or diaphragm.
Gross tumor volume (GTV) was defined as visible ex-
tent of the tumor on planning CT images, sometimes
using CT and MRI fusion images. Clinical target volume
(CTV) was equal to GTV. Internal target volume (ITV)
was expansion of CTV for the internal margin. A plan-
ning target volume (PTV) margin of 5 mm around the
ITV was added for patient positioning and set-up
uncertainty.
The SBRT plan was created with a 3-dimensional
radiotherapy planning system (Eclipse, Varian Medical
Systems, Palo Alto, CA), and an analytical anisotropic al-
gorithm (AAA version 8.6.15) was used for dose calcula-
tion. Fifty Gy in 10 fractions, 60 Gy in 10 fractions or
70 Gy in 10 fractions covering 95 % of the PTV (D95)
was delivered. The prescribed dose was selected on the
basis of the highest dose within dose constraints of the
organ at risk (Table 2). Seven tumors were prescribed
70 Gy in 10 fractions, 2 tumors were prescribed 60 Gy
in 10 fractions and 5 tumors were prescribed 50 Gy in 10
fractions. In only one case, 50 Gy in 10 fractions was
delivered to the isocenter to meet dose constraints. The
median isocenter dose was 68.8 Gy (range: 50.0–76.4 Gy).
SBRT was delivered with a linear accelerator (Clinac
23EX, Varian Medical Systems, Palo Alto, CA) using 6
MV and/or 15 MV X-ray beams with 5 to 8 coplanar and
non-coplanar multi-static ports. SBRT was performed on
consecutive treatment days. Concomitant tyrosine kinase
inhibitor or interferon was not administered.
Follow-up after SBRT
Patients underwent follow-up examinations every 3 months
for 3 years by a radiation oncologist and urologist. CT and
MRI were also performed every 6 months for 3 years.
When CT examination was performed, enhanced CT im-
ages were recommended but were not essential because it
was expected that serum creatinine had worsened. Patients
often underwent ultrasound examinations of the abdomen,
but there were no protocol requirements about ultrasound.
Renal atrophy assessment
Each functional kidney parenchyma was defined as the
contoured kidney avoiding renal cysts and renal pelvis
(Fig. 1). Kidney volume was defined as functional kidney
parenchyma minus GTV. Pretreatment functional kidney
parenchyma was delineated using planning CT images.
When the slow-rotation scanning technique was used for
radiotherapy planning, the use of pretreatment diagnostic
CT and planning CT rigid fusion images were permitted
to avoid overestimation of kidney volume. When the non-
contrast enhanced CT images were used for radiotherapy
planning, the use of diagnostic MRI and planning CT rigid
fusion images were permitted because there was no differ-
ence between CT and MRI for volumetry [18]. Post-SBRT
kidney volume was assessed using follow-up diagnostic
CT images with a slice thickness ≤ 2 mm, and the use of
follow-up CT and follow-up MRI fusion images was per-
mitted as appropriate. Volumetric analysis was performed
using Eclipse. The DVH parameter regarding kidney
volume was analyzed using Vn (%), which was defined as
percentage volume of the kidney receiving at least n dose
in Gy. Percent changes in parameters was defined as post-
SBRT parameters divided by pre-SBRT parameters in
percent.
Statistical analysis
Time to an event was calculated from the first day of
SBRT to the day an event was confirmed. Toxicity was
graded according to the National Cancer Institute Com-
mon Terminology Criteria for Adverse Events version 4.0.
Correlations between continuous variables were examined
by Spearman’s rank correlation, and r was the correlation
coefficient. Simple linear regression was applied to create
Table 2 Dose constraints for planning organ at risk volume of
10-fraction SBRT
Organ Constraints Volume
Irradiated kidney (patient with
bilateral kidneys)
30 Gy Mean
Irradiated kidney (patient with
single kidney)
26 Gy Mean
Lung 20 Gy ≤20 % of total volume
Spinal cord 35 Gy Any point
Stomach, intestine 52 Gy ≤10 cc
43 Gy ≤100 cc
Other organs 71 Gy ≤1 cc
58 Gy ≤10 cc
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a linear regression equation. Differences in continuous
variables between two groups were evaluated by the
Mann-Whitney test. Changes from pre-SBRT parameters
to post-SBRT parameters were assessed using the Wilcoxon
signed-rank test. A p-value < .05 was defined as significant
in all tests. JMP Pro v.11.2 (SAS Institute, Cary, NA) was
used for statistical analyses.
Results
Toxicity and parameter changes
The median interval between SBRT and renal atrophy as-
sessment CT was 16.9 months (range: 12.0–21.8 months),
and no patient was administered tyrosine kinase inhibitor
or interferon during that interval. The median tumor
volume shrunk from 14.8 cc (range: 3.0–55.6 cc) to
10.6 cc (range: 1.3–38.9 cc, p = 0.12). The median post-
treatment tumor volume in percent was 73.4 % (range:
41.5–144.6 %). Change in median irradiated kidney vol-
ume was from 160.4 cc (range: 99.4–295.5 cc) to 137.1 cc
(range: 70.6–258.7 cc, p < .01). The median post-treatment
irradiated kidney volume in percent was 82.6 % (range:
61.3–96.4 %, Fig. 2). Change in median contralateral kid-
ney volume was from 147.0 cc (range: 118.1–183.6 cc) to
143.9 cc (range: 114.5–191.8 cc, p = 0.73). The median
post-treatment contralateral kidney volume in percent
was 99.3 % (range: 89.4–109.0 %, Fig. 2). The median
follow-up period for all patients was 31.2 months (range:
16.2–54.2 months). During follow-up, no grade 2 or
higher renal and gastrointestinal toxicity occurred and
there was no intervention. None of the patients had pro-
gression of hypertension and none of the patients required
hemodialysis. The pre-SBRT median serum creatinine
level was 1.1 mg/dl (range: 0.4–2.0 mg/dl). The post-SBRT
peak value seen in intervals of 0.3–48.1 months was
1.6 mg/dl (p < .01), and the post-SBRT value at the time of
reporting was 1.3 mg/dl (p = 0.05). Serum creatinine of
each patient over time was showed in Fig. 3.
Univariate analysis
Spearman’s correlations between post-treatment irra-
diated kidney volume in percent and continuous vari-
ables are shown in Table 3, and the results of Mann-
Whitney test for differences between post-treatment
irradiated kidney volume in percent and categorical
variables are shown in Table 4. Significant correlation
were seen for V10 (r = −0.56, p = 0.03), V15 (r = −0.68,
p < .01),V20 (r = −0.76, p < .01), V30 (r = −0.71, p < .01),
V40 (r = −0.65, p < .01), mean irradiated kidney dose
(r = −0.66, p < .01), and magnitude of overlap between
PTV and kidney volume (r = −0.56, p = 0.03), on the other
hand, PTV did not have a correlation (r = −0.03, p = 0.91).
The observed factor of post-treatment contralateral kidney
volume in percent also had correlation (r = 0.65, p = 0.02).
There was a significant difference between the post-
treatment irradiated kidney volume in percent with and
without fiducial markers. In patients with fiducial markers
and those without fiducial markers, the post-treatment
irradiated kidney volumes in percent were 87.5 % (range:
75.6–96.4 %) and 71.4 % (range: 61.3–83.4 %, p = 0.02),
respectively, but the median isocenter doses were 73.4 Gy
(range: 50.0–76.4 Gy) and 65.5 Gy (range: 53.7–73.6 Gy),
respectively, and the isocenter doses were not significantly
different (p = 0.54). Further detailed investigation using
Spearman’s correlations revealed that V24 showed the
strongest correlation (r = −0.778, p < .01). A simple linear
regression for the post-treatment irradiated kidney volume
in percent and V24 was used for predicting a linear equa-
tion. As a result, the following linear regression equation
was obtained:
Fig. 1 Delineation of functional kidney parenchyma avoiding renal cysts and renal pelvis
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Estimated post‐treatment irradiated kidney volume %ð Þ
¼ 111:4 ‐ 0:659  V24 %ð Þ þ ε
Epsilon is the error term and its standard deviation is
6.43. The coefficient of determination was 0.60 (p < .01,
Fig. 4).
Analysis for the contralateral kidney was also performed
(n = 12). The DVH for the contralateral kidney showed that
median V5 was 0.0 % (range: 0.0–16.0 %), V10 was 0.0 %
(range: 0.0–0.4 %), and median value of mean contralateral
kidney dose was 1.1 Gy. Post-treatment contralateral kid-
ney volume in percent was 99.3 % (range: 89.4–109.0 %).
Fig. 2 Each median percent change in irradiated kidney volume (blue) and contralateral kidney volume (red)
Fig. 3 Serum creatinine levels over time. Figure 3 shows changes in serum creatinine levels of each patient over time, and the grey dashed line
shows mean serum creatinine over time
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Contralateral kidneys were almost unexposed to radiation,
and renal atrophy was not seen. Spearman’s correlation
and Mann-Whitney test were also applied, but no signifi-
cant factor for post-treatment contralateral kidney volume
in percent emerged (data not shown).
Discussion
This study was one of the few studies in which kidney
DVH parameters and other factors were analysed to find
predictors of renal atrophy after SBRT and to identify
the correlation between post-treatment irradiated kidney
volume in percent and kidney Vn. The results showed
that V20-V30 had strong correlation (r < −0.70, p < .01)
and that V24 had the strongest correlation with renal
atrophic change, and a linear equation of estimated
post-treatment irradiated kidney volume in percent with
V24 was obtained (Fig. 4). V10-V40, mean irradiated kid-
ney dose, magnitude of overlap between PTV and kidney
volume, and post-treatment contralateral kidney volume
in percent had significant relationships with renal atro-
phy. Patients with implanted fiducial markers showed a
significantly lower ratio of renal atrophic change. Com-
pensatory hypertrophy of the contralateral kidney was
not observed.
The correlation between V20 to V30 and renal atrophy
was compatible with previous findings, but the values
were slightly higher than previous findings considering
the number of fractionations [15]. There were some differ-
ences from previous reports. First, because SBRT focuses
a high dose to a local region with precise respiratory mo-
tion management, kidney DVH was less affected by inter-
fractional and intrafractional kidney movement than that
Table 3 Spearman’s correlations between post-treatment irradiated kidney volume in percent and continuous variables
Parameters Correlation of irradiated kidney
Variables Median Range Correlation coefficient P value
V5 (%) 73.7 43.3–91.8 −0.44 0.11
V10 (%) 67.3 34.7–82.5 −0.56 0.03*
V15 (%) 62.5 28.8–67.9 −0.68 < .01*
V20 (%) 53.5 24.1–64.6 −0.76 < .01*
V25 (%) 46.8 20.8–61.1 −0.77 < .01*
V30 (%) 41.9 18.3–55.4 −0.71 < .01*
V40 (%) 33.8 14.5–47.5 −0.65 0.01*
V50 (%) 20.7 6.3–42.1 −0.43 0.12
V60 (%) 13.6 0–35.5 −0.19 0.49
Mean irradiated kidney dose (Gy) 27.5 12.9–37.6 −0.66 < .01*
Pre-SBRT irradiated renal volume (cc) 160.4 99.4–295.5 0.07 0.79
GTV (cc) 14.8 3.0–55.6 0.39 0.16
PTV (cc) 79.8 28.1–146.9 −0.03 0.91
Magnitude of overlap between PTV and kidney volume (cc) 19.8 7.9–50.3 −0.56 0.03*
post-treatment contralateral kidney volume in percent (%, n = 12) 99.3 89.4–109.0 0.65 0.02*
Isocenter dose (Gy) 68.8 50.0–76.4 0.07 0.80
Age (years) 75 58–87 0.03 0.89
Creatinine change ratio (peak value/pre-SBRT) (%) 139.5 105.7–190.0 0.32 0.26
Abbreviations: Vn percentage volume of the irradiated kidney receiving at least n dose in Gy, *p < .05
Table 4 Mann-Whitney test between post-treatment irradiated kidney volume in percent and categorical variables
Change ratio of subgroup 1 Change ratio of subgroup 2 Difference
Variables Median Range Median Range P value
Gender (male, female) 82.8 69.4–96.4 75.6 613–87.5 0.31
Diabetes mellitus (Yes, No) 83.4 61.3–96.4 82.1 69.4–89.5 0.65
Antithrombotic drug (Yes, No) 82.5 69.4–96.4 81.6 61.3–95.0 0.88
Fiducial markers (Yes, No) 87.5 75.6–96.4 71.4 61.3–83.4 0.02*
Abdominal compression 81.7 69.4–96.4 82.5 61.3–95.0 0.74
4-dimensional CT (Yes, No) 82.2 61.3–96.4 82.5 71.4–89.5 1.00
*p < .05
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in conventional fractionation series. Owing to the con-
verged dose distribution, the area outside the PTV and the
contralateral kidney were minimally irradiated. Second, no
concurrent chemotherapy or adjuvant chemotherapy was
used in this study. Third, there were some differences in
morphological assessment, such as the measurement of
craniocaudal length on CT images [15]. Finally, the ana-
lysis in this study was not analysis of bilateral kidneys but
analysis of each kidney, and compensatory hypertrophy of
the contralateral kidney therefore had less effect on the
analysis (but compensatory hypertrophy was not seen in
this study) [19]. For either reason, attention must be given
to V20 to V30 of the kidney in a 10-session scheme of
SBRT, but, unfortunately, a clinically meaningful cut-off
value was vague in this study because of the limited sam-
ple size and various comorbidities.
Although the post-treatment irradiated kidney volume
in percent was not correlated with serum creatinine,
some surgical series for solitary kidney patients have
shown a relationship between renal function and re-
sidual kidney volume or volume in percent [18, 20, 21].
Sharma et al. reported that the correlation between per-
cent change in kidney parenchymal volume and percent
change in GFR (pre-/postoperative GFR) was moderate
but statistically significant. In the present study, only
two patients with a solitary kidney were enrolled, and
further analysis could therefore not be performed. In a
unilateral kidney situation, spared kidney volume from
Vn Gy may also be important considering surgical results
and radiation pneumonitis analyses [18, 22].
The post-treatment irradiated kidney volume in percent
also had a moderate positive correlation with the post-
treatment contralateral kidney volume in percent though
this factor was not predicting factor but observed one (r =
0.65, p = 0.02). The post-treatment contralateral kidney
volume in percent was 99.3 %, resulting in no occurrence
of the compensatory hypertrophy of contralateral kidney,
but that ratio ranged from 89.4 to 109.0 % and had a sig-
nificant correlation with the post-treatment irradiated kid-
ney volume in percent. This result, that is, a tendency for
enlargement of the contralateral kidney with lower post-
treatment irradiated kidney volume in percent, suggested
that host factors could affect renal remodeling even in a
setting with no additional treatment. Patients with little re-
served kidney capacity would show more atrophic change
because of the irradiation and host factors, and the con-
verse might also occur. Host factors in this study included
age and comorbidities such as cardiovascular disease (all
of the patients in this study needed administration of an
antihypertensive agent and 71 % of the patients needed
administration of antithrombotic).
A lower ratio of post-treatment kidney volume was seen
in patients with implanted fiducial markers (p = 0.02),
though prescribed doses were not different (p = 0.54). These
results were thought to be partly caused by the contribution
of fiducial markers to reduction of the internal and set-up
margins. In patients with fiducial markers and those with-
out fiducial markers, the mean values of PTV were 84.0
and 83.8 cc, respectively (p = 0.99), and the mean values of
internal volume and set-up volume (i.e., PTV minus GTV)
Fig. 4 Scatter plot and estimated linear regression equation. Scatter plot and estimated regression equation as a result of linear regression analysis of post-
treatment irradiated kidney volume in percent with V24 are shown. Dashed lines represent 95 % confidence bands. The simple linear regression equation is
as follows: Estimated post-treatment irradiated kidney volume (%) = 111.4–0.659 * V24 (%) + ε. Epsilon is the error term and its standard deviation is 6.43.
The coefficient of determination was 0.60 (p< .01)
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were 64.0 and 72.8 cc, respectively (p = 0.59). In case of
RCC, it is often difficult to distinguish the tumor from
kidney parenchyma on non-enhanced CT images and even
more difficult on non-enhanced cone beam CT images. On
the other hand, fiducial markers were easy to identify on
non-enhanced cone beam CT images, and the markers
allowed us to confirm interfractional and intrafractional
motions by using continuous X-ray images of a linear accel-
erator (on-board imager; Varian Medical Systems, Palo
Alto, CA). These facts have probably made radiation oncol-
ogists and medical physicists extend the internal and set-up
margins when gold fiducial markers were not implanted.
Although PTV did not have a relationship with post-
treatment irradiated kidney volume in percent, the magni-
tude of overlap between PTV and kidney volume had a
moderate but significant relationship (Table 4). This indi-
cated that not only the internal margin but also location of
the tumor in the kidney were important factors for renal
atrophy. When the magnitude of overlap between PTV and
kidney volume is expected to increase because of the tumor
location, implantation of fiducial markers is recommended
to reduce the internal margin and renal atrophy.
There are several limitations in the current study. This
study was a study conducted in a single institute with a
limited sample size, and patient comorbidities were not
controlled. Therefore, the exact cut-off value was vague
and a clinically meaningful cut-off value was not obtained.
The radiotherapy planning CT methods varied, and this
affected volumetric analyses to some extent. Studies with
a larger sample size and further analyses including multi-
variate analyses were needed. The periods of assessment
CT ranged from 12.0 months to 21.8 months after SBRT.
A smaller distribution of SBRT and assessment CT inter-
vals would enable more precise renal atrophy analysis.
Conclusions
V10 to V40 of the irradiated kidney and mean irradiated
kidney dose had significant correlations with the post-
treatment irradiated kidney volume in percent, with V20
to V30 showing strong correlations after SBRT for pri-
mary RCC. Attention must be paid to the dose distribu-
tion at 20 Gy to 30 Gy in 10 fractions in SBRT for RCC.
Implantation of fiducial markers might be beneficial to
reduce renal atrophy by reducing the internal margin.
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